Virus-based biopesticide

ABSTRACT

The invention relates to synthetic combinations of two or more pure genotypes cloned from the Colombian wild-type  Spodoptera frugiperda  nucleopolyhedrovirus isolate (NPV003=SfCOL) and to biopesticidal compositions having an active ingredient comprising at least two synthetic combinations and, optionally, a  S. frugiperda  granulovirus. The compositions of the invention may contain ultraviolet protectants, diluents, coating polymers, surfactants and/or pH regulators and are effective for the biological control of insects in crops, such as corn, rice, cotton, sugarcane and grasses.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a non-provisional application claiming priorityunder 35 U.S.C. §119(e)(1) from provisional application Ser. No.62/270,558, filed on Dec. 21, 2015, and which is herein incorporated byreference in its entirety.

BACKGROUND OF THE INVENTION

Field of Invention

The invention pertains to the agricultural sector, specifically tobiopesticides for biological control of pests.

Background of the Invention

Baculoviruses (from Latin baculum=staff) are viruses that specificallyinfect insects, mainly members of orders Lepidoptera, Hymenoptera andDiptera (Wang & Jehle, 2009; Duffy et al., 2006; Herniou et al., 2003;Boucias et al., 1998). They are found in the environment as occlusionbodies (OBs) (Slack & Arif, 2007), which are protein structures thatprotect the virions and grant them increased endurance in theenvironment.

The Baculoviridae family is characterized by the fact that its memberscontain a circular, double-stranded DNA genome, ranging from 80 to 180kilobase pairs (kbp). The family comprises four genera, classifiedaccording to their structural, molecular and biological characteristics:alphabaculovirus consists of nucleopolyhedroviruses (NPVs) isolated fromlepidopterans, betabaculovirus consists of granuloviruses (GVs) isolatedfrom lepidopterans, deltabaculovirus consists of NPVs isolated fromdipterans, and gammabaculovirus consists of NPVs isolated fromhymenopterans (ICTV, 2012; Jehle et al., 2006; Miele et al., 2011).

These genera are distinguished by their structural characteristics, suchas the morphology of their occlusion bodies as well as by somebiological aspects (Herniou et al., 2004; Jehle et al., 2006).Throughout the infection cycle, the formation of two viral phenotypeshas been observed: budded virions (BVs) and occlusion-derived virions(ODVs) (Theilmann et al., 2005). The two phenotypes have similarnucleocapsid structures and contain identical genetic information, butthe source and composition of their envelopes is different (Funk et al.,1997; Braunagel & Summers, 1994). BVs are responsible for effecting thesystemic infection of the host, while ODVs are responsible for spreadingthe virus between hosts. Baculoviruses are found in the environment asocclusion bodies (OBs); said bodies keep them viable for prolongedperiods of time. While the OBs of GVs normally contain only one (1)virion, the OBs of NPVs may contain multiple virions, and furthermore,said virions may in turn contain multiple nucleocapsids. (FIG. 1). Thereare various studies concerning the use of Baculoviruses as regulationfactors of some populations of insects, especially those that affectagricultural production. This technology offers considerable advantagesover chemical pesticides, including the reduction of toxic residues infood products and soil, as well as lower health hazards.

WO2014/182228 describes a method for increasing the insecticidalefficacy of a pathogenic microorganism (Spodoptera frugiperdanucleopolyhedrovirus (SfNPV)) by means of its association with amutualistic organism (yeast species of the Metschnikowia genus, such asAscomycota and Sacharomycetes; yeast species of Candida; species ofCryptococcus and species of Pseudozyma) that co-exists in intimateassociation with the larva and that stimulates the ingestion of thepathogen by said larva. However, the drawback of said method is thatduring the storage period, the metabolic activity of the mutualisticorganism can continue, thereby producing metabolites that alter viralactivity, and thus, the quality of the product.

WO2011/117411 titled “Entomopathogenic Viral Preparation”, discloses acomposition containing at least one Cydia pomonella granulovirus(characterized by a specific restriction fragment pattern), used tocontrol the codling moth larva Cydia pomonella (Lepidoptera:Tortricidae)and the Oriental peach moth C. molesta. The composition disclosedtherein does not have any application for the control of migratory pestsfrom tropical and subtropical zones of America, such as the fallarmyworm S. frugiperda.

In addition to the formulations and combinations of aforementionedagents, some studies have focused on the genetic diversity of thecontrol agents against specific pests, with the goal of selecting highlypathogenic isolates. Patent WO2014/161974 relates to new genotypes ofChrysodeixis chalcites nucleopolyhedrovirus (Chch SNPV), the process forproduction thereof and uses thereof as biological control agents. Patentapplication ES2301352 discloses six new genotypes of S. exigua multiplenucleopolyhedrovirus termed AlPstM0935, AlPstM1400, AlPstM1033,AlPstM1449, AlPstM0923, and AlPstM0657, and uses thereof, preferably asa combination of two or more genotypes, in insecticidal compositionsagainst S. exigua.

In the last few decades, various strategies to genetically modifyBaculovirus have been employed in order to increase its virulence,pathogenicity and/or insecticidal activity, which include the following:

-   -   a) insertion of the gene coding for the toxin produced by the        scorpion Buthus eupus;    -   b) insertions of the gene coding for the esterase of the        juvenile hormone produced by Heliothis virescens;    -   c) insertion of the gene for TxP-1 toxin;    -   d) insertion of the gene for AaIT toxin from the scorpion        Androctonus australis into AcNPV (Autographa californica        nucleopolyhedrovirus);    -   e) insertion of the gene for the cry toxin produced by Bacillus        thuringiensis;    -   f) insertion of the gene for diuretic hormone; g) insertion of        the scorpion neuroselective neurotoxin LqhIT2;    -   g) insertion of sequences that express substances that suppress        the appetite of Helicoverpa zea and related pests (see Brazilian        patent PI0901235-4 and patent U.S. Pat. No. 6,096,304); and    -   h) modification of the gene for chitinase, to attenuate the        lysis of the larva and increase the yield and recovery of        virions for mass production.

Although the genetic modification strategies have been shown to improvethe characteristics of the modified baculoviruses, the environmentalpolicies of several European and Latin American countries, includingColombia, do not allow the use of genetically modified organisms,because of which these microorganisms cannot be easily applied on anindustrial scale or in crop fields.

For that reason, it has been necessary to develop various types ofbiopesticidal formulations based on unmodified organisms that are highlyspecific against the pests faced and that overcome the drawbacksassociated with low efficacy and high sensitivity to UV radiation. Thus,in the study titled “Deletion Genotypes Reduce Occlusion Body Potencybut Increase Occlusion Body Production in a Colombian Spodopterafrugiperda Nucleopolyhedrovirus Population”, Corpoica describes thepurification of genotypes from a native isolate of S. frugiperdamultiple nucleopolyhedrovirus (SfMNPV). This study reports theproduction of 83 clones, 10 of which corresponded to different genotypesand were subjected to molecular and biological characterization. Theresults showed that one genotype was more pathogenic.

The study also demonstrated that the combination of this more pathogenicgenotype (termed A) with three other selected genotypes (termed C, D,and E) exhibited a lower or equal potency to that of the wild-typevirus. The conclusion of said study was that the co-occluded combinationof various genotypes in the wild is a pathogenicity regulation mechanismto ensure the persistence of the pathogen in nature and may result inlower insecticidal activity than the original wild-type virus (Barreraet al., 2013).

Additionally, in another study titled “Eudragit S100® microparticlescontaining Spodoptera frugiperda nucleopolyhedrovirus: Physicochemicalcharacterization, photostability and in vitro virus release”, Corpoicareports a method for microencapsulation of occlusion bodies of theNPV001 isolate from S. frugiperda nucleopolyhedrovirus, using a EudragitS100® methacrylic acid polymer, by means of the emulsion and solventevaporation method. The microcapsules produced exhibited a loss ofefficacy after 2 hours of irradiation with ultraviolet light (Villamizaret al., 2010), possibly due to the absence of other formulation aids andto the fact that the active ingredient is a complete wild-type virus.

In a later study titled “Microencapsulation of a Colombian Spodopterafrugiperda Nucleopolyhedrovirus with Eudragit S100® by spray drying”,Corpoica reports a formulation that is similar to the previousformulation, but with an improved microencapsulation process, abandoningthe solvent evaporation method in favor of a fluidized bed granulationmethod (Camacho et al., 2015). In this study, the size of themicrocapsules was decreased to 20 μm and photostability to UV exposureincreased.

The interaction of the various genotypes that comprise anucleopolyhedrovirus isolate may have negative, neutral or positiveeffects. For example, pure genotypes of S. exigua nucleopolyhedrovirus(SeMNPV) exhibited greater insecticidal activity that the completewild-type virus (Muñoz et al., 1998). However, in a S. frugiperdanucleopolyhedrovirus isolate from Nicaragua, the complete wild-typevirus exhibited a greater pathogenicity than the pure genotypes (Simónet al., 2004; 2005). Furthermore, the combination of some genotypesrestored the pathogenicity of the pure genotypes, but never achieved agreater pathogenicity than that exhibited by the wild-type isolate.

The inventors designed combinations of two or more pure genotypes clonedfrom the Spodoptera frugiperda nucleopolyhedrovirus isolate (NPV015through NPV019) that exhibited a greater pathogenicity than thewild-type genotype.

SUMMARY OF THE INVENTION

The present invention relates to biopesticidal compositions comprisingsynthetic combinations of two or more highly pathogenic genotypes of S.frugiperda NPV having a greater insecticidal activity than that of thewild-type virus, and optionally, biological enhancers to increase theirpathogenicity. The compositions exhibit a high efficacy againstSpodoptera frugiperda (fall armyworm), are photoresistant and stable atambient temperature.

The invention also provides a novel formulation for coating the activeingredient, comprising various formulation aids (e.g. UV filters) inorder to facilitate its implementation, protect it from light andprolong its shelf life without the need for refrigeration.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: Diagram of the structure of baculoviruses. It represents thestructure of the two morphologies of baculoviruses: Nucleopolyhedrovirus(ODVM and ODVS) and granulovirus (GV). ODVM (multiple virions) and ODV(single virion or single nucleopolyhedrovirus SNPV) are immersed in anocclusion body (CI or OB) consisting of a protein matrix termedpolyhedrin in NPVs and granulin in GVs.

ODVS: several ODVs, V: virion, NC: nucleocapsid.

FIG. 2: Diagram of the process for obtaining genotypes of Spodopterafrugiperda nucleopolyhedrovirus.

A. Obtaining a wild-type SfMNPV isolate

B. Obtaining individual genotypic variants

C. Preparation of synthetic combinations of the virus.

FIG. 3: Photograph of the agarose gel with restriction fragment patterns(REN) produced by the PstI enzyme from the Spodoptera frugiperdagranulovirus isolate VG008 and the genotypes of S. frugiperdanucleopolyhedrovirus NPV015-NPV019.

FIG. 4: Diagram of the fragments produced by the PstI enzyme from theSpodoptera frugiperda granulovirus isolate VG008 and the genotypes of S.frugiperda nucleopolyhedrovirus NPV015-NPV019.

FIG. 5: Graph of the effect of the formulation on the stability of theinsecticidal activity of the wild-type virus NPV003 and the combinationof genptNPV0es and granulovirus at 28° C.

NPV003-nf: Unformulated wild-type virus NPV003; NPV003-f: Formulatedwild-type virus NPV003 and formulated granulovirus.

FIG. 6: Graph of the contaminating microorganism content of theformulated and unformulated wild-type virus NPV003 and of the formulatedcombination of genotypes and granulovirus, stored for three months at28° C.

NPV003-nf: Unformulated wild-type virus NPV003; NPV003-f: Formulatedwild-type virus NPV003 and formulated granulovirus.

FIG. 7: Graph of efficacy vs irradiation time from the photostabilitystudy of the formulated and unformulated wild-type virus NPV003 and ofthe formulated combination of genotypes and granulovirus

NPV003-nf: Unformulated wild-type virus NPV003; NPV003-f: Formulatedwild-type virus NPV003 and formulated granulovirus.

DETAILED DESCRIPTION OF THE INVENTION

The present invention comprises a synthetic combination of two or morepure genotypes cloned from the isolate of nucleopolyhedrovirus (NPV015through NPV019) from Spodoptera frugiperda (NPV-003=SfCOL), co-occludedin a single occlusion body, or a combination of occlusion bodies ofindividual genotypes, and optionally, a biological or chemical enhancer(e.g. granulovirus isolates, insect nucleopolyhedroviruses or proteinsderived therefrom). The invention also considers compositions comprisingsaid synthetic combinations along with one or more excipients, adjuvantsand/or carriers that are chemically and environmentally suitable forthis type of product.

The pure genotypes can be obtained in accordance with the processdescribed in FIG. 2. A purified viral suspension of NPV0003 is used toinfect Spodoptera frugiperda larvae by oral administration, andhemolymph is extracted from the larvae at the specific point in thecycle during which budded virions are present (with a singlenucleocapsid and a single genome). Then, by means of several dilutions,insect cells of the Sf9 line (S. frugiperda cell line) are infected.

In order to obtain the combinations of co-occluded genotypes in a singleocclusion body, the occlusion-derived virions can be released by meansof treatment with alkaline solutions, so they can later be injectedsimultaneously into the larvae. The co-occlusion of the selectedgenotypes occurs during the infection process.

In order to obtain the combination of occlusion bodies having individualgenotypes, individual cells containing a single genotype are selectedand multiplied by means of injection into larvae, from which eachindividual genotype variant is purified after the death of the larvae.From these individual genotypes, combinations of the genotypes that werepreviously selected for their insecticidal activity can be produced.

In one embodiment of the invention, all of the genotypes ofnucleopolyhedrovirus NPV003 and the S. frugiperda granulovirus isolateVG008 can be digested with PstI enzyme and the resulting bands can beobserved in 1% agarose gel stained with ethidium bromide (FIG. 3). Therestriction fragments resulting from the digestion of genomic DNA byPstI enzyme are labeled alphabetically, beginning with the letter A forthe largest fragment and consecutively down to the smallest resultingfragment (FIG. 4).

The genotypes of nucleopolyhedrovirus and granulovirus are characterizedby a specific band pattern resulting from genome cleavage with PstIenzyme, with fragments of different weights. Table 1 shows the estimatedsize of the restriction fragments produced by the PstI enzyme from theS. frugiperda granulovirus isolate VG008 and the genotypes of S.frugiperda nucleopolyhedrovirus NPV015 through NPV019.

TABLE 1 Fragment NPV015 NPV016 NPV017 NPV018 NPV019 VG008 A 28084 2808428084 28084 28084 14750 B 24926 24926 24926 24926 24926 14749 C 1246512465 12465 12465 12465 14749 C′ 9200 D 8864 8864 8864 8864 8864 11761 E8481 8481 8481 8481 8481 8921 E′ 7800 F 7079 7079 7079 7079 8784 G 69326932 6932 6932 6932 8397 H 6124 6124 6124 6124 6124 8030 I 5182 51825182 5182 5182 6969 J 4899 4899 4899 4899 4899 6660 K 4887 4887 48876430 L 4769 4769 4769 4769 4769 5474 L′ 4200 M 3575 5258 N 2953 4552 N′2700 O 2112 2112 2112 2112 2112 3485 P 1339 1339 1339 1339 1339 2212 Q1228 1228 1228 1228 1228 1705 R 1447 S 1039 T 974 U 636 V 521 W 400 X300 Total 133899 130284 129384 129492 127371 138203

The bands that characterize each genotype are:

-   -   NPV015: A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q    -   NPV016: A, B, C, D, E, E′, F, G, H, I, J, L, O, P, Q    -   NPV017: A, B, C, D, E, F, G, H, I, J, L, L′, N′, O, P, Q    -   NPV018: A, B, C, C′, D, E, G, H, I, J, K, L, O, P, Q    -   NPV019: A, B, C, D, E, F, G, H, I, J, K, L, O, P, Q    -   VG008: A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S,        T, U, V, W, X

The sequences of the amplified fragments are:

>Sf23 (SEQ ID. No. 1) GCTTGTGCGTTGTCGTTGATCGTACAGAGATAATAACTAAAATACACCCCATCACTAAGAAAAAAATTAAAATTGACGTATCTAATAAATACATTAATAGGATGAAGAAGACGCTGATAAAGTGGGGCTATCCTGTGAAATTTGCAAAATTTGACGAGTTTAAAGGATACAAGTACGACATTGACACGGACGACTGGGAC CGAGTCGACTACAA >Sf24(SEQ ID No. 2) TCGTCGGCATCATACTGCTCTCGGTGGACAAGTTTGTGTCCATACCCATCATACAGCTGTACCAGATCGCGTACCAGCAACTGCAGATATCGCCGTTTTACGTGACGCTGACGCTCATGCTGCTCACCACCGTTGGTGGACTGTCGACGA AAACCATGCGAACGTG

The isolate VG008, for its part, amplified a specific 203 bp region withthe primers SFGV 24.1-5′ CCGATAAGGTTATATCTGA 3′ (SEQ ID No. 3) and SFGV24.2 5′ TCAATAACTTCTTCGTGCA 3′. (SEQ ID No. 4) The sequence of theamplified fragment is the following:

>SFGV24 (SEQ ID No. 5)AGATATCACCTTTGAAGACATTGATTCGATCTACGACGCAGAAACGCAACTCGACAAAGCTTACGATAACGTTAAATGGGAGGACAAATACAAGGAATTGCTAGACCAATACAATAAAGATAAAGAAAAATGGGAGAAAAAATACACAGAGCTTATGAATCAAAATACAGTCGACGAGGACAAATGGACAACAGAAAAGA AGA

The genotypes of the nucleopolyhedrovirus (NPV015, NPV016, NPV017,NPV018, NPV019) are also characterized by the amplification of twospecific 214 and 166 base-pair fragments with the primers Sf23.1(5′-GCTTGTGCGTTGTCGTTGAT-3′) (SEQ ID No. 6) and Sf23.2(5′-TTGTAGTCGACTCGGTCCCA-3′) (SEQ ID No. 7), and with the primers Sf24.1(5′-TCGTCGGCATCATACTGCTC-3′) (SEQ ID No. 8.) and Sf24.2(5′-CACGTTCGCATGGTTTTCGT-3′) (SEQ ID No. 9) respectively. This region,that is present and specific to all of these genotypes, was not found inother wild-type isolates. The genotypes of the nucleopolyhedrovirus(NPV015, NPV016, NPV017, NPV018, NPV019) are deposited in the Nation'sgermplasm bank for microorganisms pertaining to biological control,managed by Corpoica and located at the Centro de InvestigacionesTibaitatá [Tibaitatá Research Center], Mosquera (Cundinamarca,Colombia). The biological materials have also been deposited with theAmerican Type Culture Collection under accession number SD-7011.

In one embodiment of the invention, the synthetic combination comprisesat least the genome of a virions that exhibits the band patternresulting from cleavage with PstI enzyme, listed in Table 1.

In a more preferred embodiment, the synthetic genotype combinations are:

-   -   1. Synthetic combination No. 1: NPV015+NPV016+NPV017;    -   2. Synthetic combination No. 2: NPV015+NPV018+NPV019;    -   3. Synthetic combination No. 3: NPV015+NPV016+NPV017+VG008;    -   4. Synthetic combination No. 4: NPV015+NPV018+NPV019+VG008;    -   5. Synthetic combination No. 5: NPV015+NPV018+NPV017+VG008        protein;    -   6. Synthetic combination No. 6: NPV015+NPV018+NPV019+VG008        protein.

Synthetic combinations 1 through 4 are obtained in accordance with theprocess illustrated in FIG. 2. For the specific case of syntheticcombinations 5 and 6, once the combinations of viral genotypes areobtained, VG008 proteins are added as enhancers. The VG008 proteins cancorrespond to the total or partial protein extract obtained from theocclusion bodies, to the proteins purified therefrom, or syntheticallyproduced proteins. The main proteins are of the enhancin and chitinasevarieties.

The synthetic combinations can be included in biopesticidalcompositions. In addition to the synthetic NPV combinations, thecompositions also include various carriers, coadjuvants, ultravioletprotectants, diluents, coating polymers, surfactants and pH regulatorsin order to establish the proprietary shape and characteristics of theend product (e.g. form emulsions), improve its stability and increaseits shelf life during storage. The total concentration of syntheticcombinations in the compositions of the invention is preferably between0.1% and 99.9% (w/w).

For the purposes of the present invention, a carrier can be defined as asubstance or mixture of substances (e.g. solvents, solutions, emulsionsand suspensions) capable of holding the synthetic combinations withoutaffecting their ability to perform their desired function.

The ultraviolet protectants are selected from the group consisting of:pigments, such as iron oxides, titanium dioxide, zinc dioxide;colorings, such as lycopene, betaine, bixin, curcumin, chlorophyll,tartrazine, saffron, carminic acid, other food colorings and opticalbrighteners, such as stilbene derivatives.

The diluents are selected from the group consisting of: clays, such askaolin, bentonites, sepiolites, starches, cellulose derivatives andstearates, such as magnesium stearate. The coating polymers are selectedfrom the group consisting of: natural polymers, such as lignin,cellulose, starch, carrageenan, alginate, gum arabic, xanthan gum,dextrans, synthetic polymers, such as acrylic derivatives (polymethylacrylates) and polyesters.

The Ph regulators are selected from the group consisting of: buffers,such as phosphate, citrate, carbonate, borate phthalate buffer andcombinations thereof. The surfactants are selected from the groupconsisting of: anionic surfactants, such as carboxylate esters andpolyethoxylated carboxylate derivatives; cationic surfactants, such asbenzalkonium chloride and cetylpyridinium chloride; nonionicsurfactants, such as polysorbates (Tween 20-80), sorbitan esters (Span20-80) and octyl phenol ethoxylate (Triton); and amphoteric surfactants,such as betaines and sultaines.

The compositions of the invention can be in solid form as powders,granules, tablets or pellets, in liquid form as suspensions,emulsifiable concentrates or emulsions, and can be applied to foliage,to soil, by dusting, by irrigation and/or by spraying, and can be mixedwith compost, fertilizers, other bio-additives, vegetable extracts andagrochemicals. Additionally, the compositions can optionally containbiological or chemical enhancers of insecticidal activity.

The concentration of occlusion bodies in the active ingredient of thecompositions is between 1×10⁴ and 1×10¹¹ occlusion bodies/mL in all ofthe synthetic viral combinations described hereinbefore. Thecompositions include different coadjuvants with specific functions toimprove stability during storage and the photostability of the viralparticles under solar radiation.

In an additional preferred embodiment, the compositions of the inventionare formulated as a wettable powder, which includes a bioadhesivepolymer that mitigates the effect of solar radiation and increases theadhesion of the virus to plant tissue and the intestinal mucosa of theinsect. The specific compositions of this composition stabilize theocclusion bodies of the virus during storage, thereby increasing theshelf life of the bioproduct.

Some of the preferred embodiments of the compositions of the presentinvention are described in Tables 2 through 7.

TABLE 2 Wettable powder composition - base COMPONENT (% w/w) on a drybasis Viral suspension with a concentration 0.50-8.50 between 10⁴ and10¹¹ occlusion bodies/mL* Kaolin 70.00-95.00 Red iron oxide  0.10-10.00Lycopene E160d 0.10-15.0 Methacrylic acid copolymer (Eudragit 1.00-10.00 S100 ®) Potassium dihydrogen phosphate 0.01-1.00 Sodiumphosphate dibasic 0.10-1.00 *Corresponds to any of the synthetic viralcombinations described herein.

TABLE 3 Wettable powder composition No. SfNPV003-1 COMPONENT (% w/w) ona dry basis Viral suspension with a concentration 1.35 between 10⁴ and10¹¹ occlusion bodies/mL* Kaolin 77.95 Red iron oxide 1.36 LycopeneE160d 13.61 Methacrylic acid copolymer (Eudragit 5.48 S100 ®) Potassiumdihydrogen phosphate 0.04 Sodium phosphate dibasic 0.21 *Corresponds toany of the synthetic viral combinations described herein.

TABLE 4 Wettable powder composition No. SfNPV003-2 COMPONENT (% w/w) ona dry basis Viral suspension with a concentration 2.50 between 10⁴ and10¹¹ occlusion bodies/mL* Kaolin 77.80 Red iron oxide 1.36 LycopeneE160d 13.61 Methacrylic acid copolymer (Eudragit 4.48 S100 ®) Potassiumdihydrogen phosphate 0.04 Sodium phosphate dibasic 0.21 *Corresponds toany of the synthetic viral combinations described herein.

TABLE 5 Wettable powder composition No. SfNPV003-3 COMPONENT (% w/w) ona dry basis Viral suspension with a concentration 2.50 between 10⁴ and10¹¹ occlusion bodies/mL* Kaolin 77.80 Red iron oxide 2.36 LycopeneE160d 13.61 Methacrylic acid copolymer (Eudragit 3.48 S100 ®) Potassiumdihydrogen phosphate 0.04 Sodium phosphate dibasic 0.21 *Corresponds toany of the synthetic viral combinations described herein.

TABLE 6 Emulsifiable liquid concentrate composition - base (% w/w) on adry COMPONENT basis Viral suspension with a concentration 0.66-6.60between 10⁴ and 10¹¹ occlusion bodies/mL* Methacrylic acid copolymer(Eudragit 0.00-5.00 S100 ®) Kaolin  2.0-30.00 Lycopene E160d 0.05-5.00Boric acid 0.05-5.00 Vegetable oil 10.00-70.00 Oleic acid  3.00-10.00Tween 80  1.00-10.00 Span 60  1.00-10.00 *Corresponds to any of thesynthetic viral combinations described herein.

TABLE 7 Emulsifiable concentrate composition No. SfNPV003-4 COMPONENT (%w/w) on a dry basis Viral suspension with a concentration 3.40 between10⁸ and 10¹¹ occlusion bodies/mL Methacrylic acid copolymer (Eudragit0.15 S100 ®) Kaolin 10.60 Lycopene E160d 2.84 Boric acid 0.50 Vegetableoil 66.49 Oleic acid 8.01 Tween 80 4.24 Span 60 3.77 *Corresponds to anyof the synthetic viral combinations described herein.

The biopesticidal compositions of the invention are effective for use inthe biological control of insects from orders Hymenoptera, Diptera andLepidoptera, preferably against Spodoptera frugiperda in all of its hostcrops, especially corn, rice, cotton, sugarcane and grasses.Furthermore, obtaining the compositions of the present invention doesnot require advanced technology and these are viable for application inagricultural industry.

The following Examples describe the present invention in greater detail.However, the inventive concept is not limited to these examples.

Examples Example 1. Obtaining the Genotypes

A S. frugiperda nucleopolyhedrovirus (NPV003) and a S. frugiperdagranulovirus (VG008) were isolated from larvae collected from a pasturein the Department of Córdoba (Colombia) (Gómez et al., 2010). Purifiedpolyhedra containing various genotypes were naturally obtained from thenucleopolyhedrovirus NPV003.

The process for obtaining pure genotypes is described in FIG. 2, whichshows how the purified viral suspension of NPV0003 were used to infectS. frugiperda larvae by oral administration, and hemolymph was extractedfrom the larvae at the point in the cycle during which budded virionswere present (with a single nucleocapsid and a single genome).

By means of several dilutions, insect cells of the Sf9 line (S.frugiperda cell line) were infected. Then, individual cells containing asingle genotype were selected and multiplied by means of injection intolarvae, from which each individual genotype variant was purified afterthe death of the larvae. From these individual genotypes, combinationsof the genotypes that were previously selected for their insecticidalactivity were produced. Initially, the virions derived from treatment ofocclusion bodies with alkaline solutions were released and injected intolarvae. The co-occlusion of the selected genotypes occurred during theinfection process. Meanwhile, combinations of the genotypes wereobtained by combining the occlusion bodies that contain individuallyselected variants.

Example 2. Insecticidal Activity of the Viral Combinations

Insecticidal activity was evaluated by means of a bioassay in accordancewith the droplet method described by Hughes and Wood (1981) and usingthe previously determined Lethal Concentration 50 (CL₅₀) of thewild-type virus NPV003, equal to 1×10⁵ CI/mL. The treatments correspondto the wild-type virus NPV003, synthetic combination No. 1, syntheticcombination No. 2 and an absolute control. The assay employed threerepetitions per treatment, each with 15 neonate larvae, in a completelyrandomized design, and mortality was evaluated 7 days after inoculation.The results were analyzed by means of an ANOVA and a least significantdifference (LSD) test (95%).

As a result of the assay, the absolute control exhibited a mortalityrate of 6.66%, while the evaluated treatments exhibited significantlygreater mortality rates (p<0.05). The employed concentration ofwild-type virus NPV003 resulted in the expected mortality rate, 53.33%,while the assayed combinations (synthetic combinations 1 and 2)exhibited a significant increase (p=0.0168) in insecticidal activity,with mortality values of 80% and 70% for combinations 1 and 2,respectively.

The results are shown in Table 8, which confirm the enhancing effect ofthe synthetic combinations with the potential to be used as activeingredients in bioinsecticidal compositions.

TABLE 8 Mortality rate of neonate S. frugiperda larvae treated withwild-type virus NPV003 and two synthetic combinations at 1 × 10⁵ CI/mLRepetition NPV003 Combination Combination Control 1 53.00 67.00 73.006.66 2 46.00 87.00 73.00 6.66 3 60.00 87.00 66.00 6.66 Average 53.0080.33 70.66 6.66

Example 3. Stability of the Compositions in Storage Conditions

For a composition formulated in accordance with Table 4 (No. SfNPV003-1based on viral combination No. 1), 0.5 g samples were packed intovacuum-sealed metalized pouches having a 2 cm width and a 4 cm length.Formulated (formula No. SfNPV003-1 (NPV003-f)) and unformulated(NPV003-nf) wild-type isolate NPV003 were used as control treatments.

Nine samples of each treatment were stored in an incubator at 28±2° C.Insecticidal activity was evaluated by means of a bioassay beforestorage and after 1, 2 and 3 months of storage, in accordance with thedroplet method described by Hughes and Wood (1981) and using thepreviously determined CL₉₀ of each viral inoculum.

To quantify the contaminant content, 9 mL of 0.1% Tween 80® were addedto one of the samples and decimal dilutions down to 1×10⁵ wereperformed. 100 μL from the last three dilutions were spread onto Petridishes:

-   -   i) for the assessment of molds in potato dextrose agar medium        supplemented with 0.1% Triton (PD agar+Triton);    -   ii) for the quantification of yeasts in yeast extract malt agar        medium (YM agar), and;    -   iii) for bacterial counting in nutrient agar medium.

Each dilution was spread in triplicate. The result was expressed as thenumber of colony-forming unites per gram of product (CFU/g). Theexperimental design was completely randomized, with repeatedmeasurements over time and all measurements performed in triplicate.

FIG. 5 shows that the wild-type virus NPV003 exhibited a 33% loss of itsinsecticidal activity when it was stored as an unformulated viralsuspension for three months at 28° C. On the other hand, the wild-typevirus NPV003 and the viral combination (combination 1) formulated as awettable powder only exhibited an 11% loss of insecticidal activity whenthey were subjected to the same conditions as the unformulated virusNPV003, which proves the stabilizing effect offered by the formulationduring the storage period.

Under the conditions of the study, the formulation reduced viralinactivation by 66% after three months of storage at a temperature of28° C., an effect that could be increased at lower temperatures or inrefrigeration conditions.

The loss kinetics of efficacy versus storage time of the formulatedcombination was fit to a curve of first-order kinetics with a 0.98correlation coefficient. The shelf life of the product was estimatedusing the equation produced by this mathematical model, using 70% as theminimum acceptable efficacy rate. Based on this information, the productwould be stable for 8 months of storage at 28° C., that is to say,without the need for a cold chain during transport, which reducesdistribution costs and provides a time window large enough for the saleof the bioadditive.

As for the contaminant content, shown in FIG. 6, the microorganismcontent in the treatment corresponding to the unformulated suspension ofwild-type virus NPV003 increases in direct proportion to the storagetime, in increments greater than one logarithmic unit. On the otherhand, the two tested formulated treatment (wild-type virus NPV003 andthe viral combination, in wettable powder form), exhibited a significantreduction in contaminants, which was inversely proportional to thestorage time.

This behavior is possibly due to the effect of the formulation process,which involves the removal of water from the product until the finalhumidity level in the product is less than 5%. The drying process causesthe death of microorganisms, thereby reducing the contaminant load bytwo logarithmic units and then, the low humidity inhibits microbialmetabolism and prevents the proliferation of contaminants, such asbacteria and fungi that are still viable in the formulation.

The reduction of contaminants in the formulation may be associated withthe greater stability of its insecticidal activity, bearing in mind thatmicroorganisms can negatively affect the integrity of viral particlesduring storage.

Example 4. Photostability Assay Under UVB Radiation

The treatments evaluated in this assay were unformulated wild-type virusNPV003 (aqueous suspension), wild-type virus NPV003 formulated as awettable powder in accordance with formula No. SfNPV003-1 from Table 4,and the formulated viral combination (combination No. 1), alsoformulated as per SfNPV003-1. Suspensions were prepared at aconcentration of 2×10⁷ CI/mL.

200 μL of each suspension were placed in 5 wells of a row of aflat-bottomed 96-well microplate. The microplate was irradiated with amonochromatic light (wavelength=302 nm) for 2, 4 and 6 hours, at adistance of 10 cm from the light source. Before beginning the exposureto light, the first column of wells of the microplate was covered withaluminum foil (one well of each concentration), which corresponded tothe treatment of no exposure of the virus to radiation (time=0 hours).

Every 2 hours, until 6 hours had elapsed, the next column of wells wascovered, so that each column of the microplate represented a differentduration of exposure to ultraviolet-B radiation. Subsequently, 200 μL ofa 4% sucrose solution, which contained 1% blue food coloring, were addedto each well, and a bioassay was performed to determine theirinsecticidal activity, in accordance with the droplet method describedby Hughes and Wood (1981).

The formula from Schneider-Orelli (Zar 1999) was used to determine theirefficacy, and these efficacy values were then used to calculate theremaining percentage of original activity using the following equation(Shapiro, 1989):

% Original Activity=(B/A)×100

-   -   where:    -   A: Efficacy of the unexposed virus    -   B: Efficacy of the virus exposed to UV radiation

The normality of the data was estimated by means of a Shapiro-Wilk test(95%) and the homogeneity of variance was estimated using Bartlett'stest (95%). Subsequently, the differences between treatments were provenby means of an LSD test (95%).

FIG. 7 shows the results of the assay, which demonstrates that theunformulated virus NPV003 exhibited a progressive and significant lossin activity as the irradiation time elapsed, exhibiting 49% inactivationafter 6 hours of exposure to UVB light.

The wild-type virus NPV003 formulated as a wettable powder in accordancewith formula No. SfNPV003-1 exhibited 11.6% inactivation, while theviral combination also formulated in accordance with formula No.SfNPV003-1 exhibited 5.8% inactivation, which confirms thephotoprotectant effect of the formulation, which would prolong thepreservation of the viral particles in the environment.

It should be noted that efficacy after 6 hours of irradiation wassignificantly greater for the formulated product based on the viralcombination than the formulated product based on the wild-type virusNPV003, which also suggests that the viral combination possiblycontributes to the greater photostability of the formulated product.

REFERENCES

-   1. Boucias, D. G., Pendland, J. C. 1998. Baculoviruses, in: Kluwer    (Ed.), Principles of insect pathology. Academic Publishers, Norwell,    pp. 111-146.-   2. Braunagel, S. C., Summers, M. D. 1994. Autographa californica    nuclear polyhedrosis virus, PDV, and ECV viral envelopes and    nucleocapsids: structural proteins, antigens, lipid and fatty acid    profiles. Virology 202: 315-328.-   3. Duffy, S. P., Young, A. M., Morin, B., Lucarotti, C. J., Koop, B.    F., & Levin, D. B. 2006. Sequence analysis and organization of the    Neodiprion abietis nucleopolyhedrovirus genome. Journal of Virology    80: 6952-63.-   4. Funk, C. J., Braunagel, S. C., Rohrmann, G. F. 1997. Regulation    of Baculovirus Late and Very Late Gene Expression. New York: Plenum-   5. Gómez, J., Guevara, J., Cuartas, P., Espinel, C.,    Villamizar, L. 2013. Microencapsulated Spodoptera frugiperda    nucleopolyhedrovirus: insecticidal activity and effect on arthropod    populations in maize. Biocontrol Science and Technology 23: 829-846.-   6. Gómez, J.; Guevara, J.; Barrera, G.; Cotes, A.;    Villamizar, L. 2010. Aislamiento, identificación y caracterización    de nucleopoliedrovirus nativos de Spodoptera frugiperda en Colombia.    [Isolation, identification and characterization of Spodoptera    frugiperda wild-type nucleopolyhedrovirus in Colombia.] Revista    Facultad Agronomia. Medellín 63: 5511-5520.-   7. Herniou, E. A., Olszewski, J. A., Cory, J. S.,    O'Reilly, D. R. 2003. The genome sequence and evolution of    baculoviruses. Annual Review of Entomology 48: 211-234.-   8. Herniou, E. A, Olszewski, J. A., O'Reilly, D. R.,    Cory, J. S. 2004. Ancient coevolution of baculoviruses and their    insect hosts. Journal of Virology 78: 3244-3251.-   9. Hughes, P. R., Wood, H. A. 1981. A synchronous peroral technique    for the bioassay of insect viruses. Journal of Invertebrate    Pathology 37: 154-159.-   10. ICTV, 2012. International Committee on Taxonomy of viruses.-   11. Inceoglu, A. B., Kamita, S. G., Hammock, B. D. 2006. Genetically    modified baculoviruses: a historical overview and future outlook.    Advances in virus research 68: 323-360.-   12. Jehle, J. A., Lange, M., Wang, H. L., Hu, Z. H., Wang, Y. J.,    Hauschild, W. 2006. Molecular identification and phylogenetic    analysis of baculoviruses from Lepidoptera. Virology 346: 180-193.-   13. Jenkins, N. & Grzywacz, D. 2003. Towards the standardization of    quality control of fungal and viral biocontrol agents. In Qual    Control Prod Biol Control agents theory Test Proced, pp. 247-263.    Edited by J. C. van Lenteren. Wallinford, UK: CAB International.-   14. Lahlalia R, Serrhinib M, Jijakl M. 2006. Studying and modelling    the combined effect of temperature and water activity on the growth    rate of P. expansum. International Journal of Food Microbiology.    103:315-322.-   15. Lasa, R., Pagola, I., Ibanez, I., Belda, J. E., Williams, T.,    Caballero, P. 2007. Efficacy of Spodoptera exigua multiple    nucleopolyhedrovirus as a biological insecticide for beet armyworm    control in greenhouses of southern Spain. Biocontrol Science and    Technology 17: 221-232.-   16. Miele, S. A. B., Garavaglia, M. J., Belaich, M. N., 2011.    Baculovirus: molecular insights on their diversity and conservation.    Int. Journal of Evolutionary Biology 211: 37-42.-   17. Muñoz, D., Castillejo, J. I., Caballero, P. 1998. Naturally    occurring deletion mutants are parasitic genotypes in a wild-type    nucleopolyhedrovirus population of Spodoptera exigua. Applied and    Environmental Microbiology 64: 4372-4377.-   18. Muñoz, D., Murillo, R., Krell, P. J., Vlak, J. M.,    Caballero, P. 1999. Four genotypic variants of a Spodoptera exigua    nucleopolyhedrovirus (Se-SP2) are distinguishable by a hypervariable    genomic region. Virus Research 59: 61-74.-   19. Murillo, R., Muñoz, D., Williams T., Caballero, P. 2006. Genetic    and phenotypic variability in Spodoptera exigua nucleopolyhedrovirus    isolates from greenhouse soils in southern Spain. Biological Control    38: 157-175.-   20. Ravensberg, W. 2011. A roadmap to the successful development and    commercialization of microbial pest control products for control    arthropods. Vol. 10.-   21. Santos A., García M., Cotes A. M., Villamizar L. 2012. Efecto de    la formulación sobre la vida util de bioplaguicidas a base de dos    aislamientos colombianos de Trichoderma koningiopsis Th003 y    Trichoderma asperellum Th034. [Effect of the formulation on the    shelf life of biopesticides based on two Colombian isolates from    Trichoderma koningiopsis Th003 and Trichoderma asperellum Th034.]    Revista Iberoamericana de Micología 29:150-156.-   22. Schneider-Orelli, O., 1947. Entomologisches Praktikum-Einfürung    in die land—un forstwirtschafliche Insektenkunde. Sauerländer & Co,    Aarau, Germany.-   23. Shapiro, M. 1989. Congo red as an ultraviolet protectant for the    gypsy moth (Lepidoptera:Lymantriidae) nuclear polyhedrosis virus.    Journal of Economical Entomology. 82: 548-550.-   24. Simón, O., Williams, T., López-Ferber, M., Caballero, P., 2004.    Genetic structure of a Spodoptera frugiperda nucleopolyhedrovirus    population: High prevalence of deletion genotypes. Applied and    Environmental Microbiology 70: 5579-5588.-   25. Simón, O., Williams, T., López-Ferber, M., Caballero, P., 2005.    Functional importance of deletion mutant genotypes in an insect    nucleopolyhedrovirus population. Applied and Environmental    Microbiology 71, 4254-4262.-   26. Slack, J., Arif, B. M., 2007. The baculoviruses    occlusion-derived virus: Virion structure and function. Advances in    virus research 69: 99-165.-   27. Theilmann, D. A., Blissard, G. W., Bonning, B., Jehle, J.,    O'Reilly, D. R., Rohrmann, G. F., Theim, S., Vlak, J., 2005. Family    baculoviridae. In: Fauquet, C. M., Mayo, M. A., Maniloff, J.,    Desselberger, U., Ball, L. A. (Eds.), Virus Taxonomy, Eighth Report    of the International Committee on Virus Taxonomy. Elsevier Press,    San Diego, pp. 177-185.-   28. Villamizar, L., Barrera, G., Cotes, A. M. & Martinez, F. 2010.    Eudragit S100 microparticles containing Spodoptera frugiperda    nucleopolyhedrovirus: physicochemical characterization,    photostability and in vitro virus release31. Journal of    Microencapsulation 27: 314-24-   29. Villamizar, L., Zeddam, J., Espinel, C., Cotes, A. M. 2005.    Implementación de técnicas de control de calidad para la producción    de un bioplaguicida a base del granulovirus de Phthorimaea    operculella PhopGV. [Implementation of quality control techniques    for the production of a biopesticide based on Phthorimaea    operculella granulovirus PhopGV.] Revista Colombiana de Entomología    31: 127-132.-   30. Wang, Y.; Jehle, J. A. 2009. Nudiviruses and other large,    stranded circular DNA viruses of invertebrates: New insights on an    old topic. Journal of Invertebrate Pathology 101: 187-193. Zar, J.    1999-   31. Biostatistical Analysis. 4th Edition Prentice Hall. New Jersey.

1. A synthetic combination comprising two or more cloned genotypes frominsect-pathogenic nucleopolyhedroviruses (NPVs).
 2. The syntheticcombination of claim 1, wherein two or more cloned genotypes frompathogenic nucleopolyhedroviruses selected from the group consisting of:NPV015, NPV016, NPV017, NPV018, NPV019, in which: clones NPV015, NPV016,NPV017, NPV018, NPV019 are characterized by the patterns of restrictionwith PstI enzyme that comprise the following bands, NPV015: A, B, C, D,E, F, G, H, I, J, K, L, M, N, O, P, Q; NPV016: A, B, C, D, E, E′, F, G,H, I, J, L, O, P, Q; NPV017: A, B, C, D, E, F, G, H, I, J, L, L′, N′, O,P, Q; NPV018: A, B, C, C′, D, E, G, H, I, J, K, L, O, P, Q; NPV019: A,B, C, D, E, F, G, H, I, J, K, L, O, P, Q; according to the followingtable: Fragment NPV015 NPV016 NPV017 NPV018 NPV019 VG008 A 28084 2808428084 28084 28084 14750 B 24926 24926 24926 24926 24926 14749 C 1246512465 12465 12465 12465 14749 C′ 9200 D 8864 8864 8864 8864 8864 11761 E8481 8481 8481 8481 8481 8921 E′ 7800 F 7079 7079 7079 7079 8784 G 69326932 6932 6932 6932 8397 H 6124 6124 6124 6124 6124 8030 I 5182 51825182 5182 5182 6969 J 4899 4899 4899 4899 4899 6660 K 4887 4887 48876430 L 4769 4769 4769 4769 4769 5474 L′ 4200 M 3575 5258 N 2953 4552 N′2700 O 2112 2112 2112 2112 2112 3485 P 1339 1339 1339 1339 1339 2212 Q1228 1228 1228 1228 1228 1705 R 1447 S 1039 T 974 U 636 V 521 W 400 X300 Total 133899 130284 129384 129492 127371 138203

clones NPV015, NPV016, NPV017, NPV018, NPV019 are also characterized bythe fact that they comprise the sequences for genes sf23 (SEQ ID No. 1)and sf24 (SEQ ID No. 2), which are not amplified in other isolates of S.frugiperda nucleopolyhedrovirus.
 3. The synthetic combination of claim2, selected from the group consisting of: NPV015+NPV016+NPV017; andNPV015+NPV018+NPV019
 4. The synthetic combination of claim 3, whereinthe genotypes are individually occluded in an occlusion body orco-occluded in the combination.
 5. The synthetic combination of claim 4,further comprising biological enhancers selected from granulovirusisolates, insect nucleopolyhedroviruses or proteins derived therefrom.6. The synthetic combination of claim 5, wherein the biological enhanceris granulovirus VG008 and exhibits the pattern of restriction with PstIenzyme that comprises the following bands: VG008: A, B, C, D, E, F, G,H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X. according to thetable from claim 1; further wherein the VG008 isolate's genome comprisesa SFGV24 (SEQ ID No. 5).
 7. The synthetic combination of claim 6,selected from the group consisting of: NPV015+NPV016+NPV017+VG008; andNPV015+NPV018+NPV019+VG008; and wherein the genotypes are individuallyoccluded in an occlusion body or co-occluded in the combination.
 8. Thesynthetic combination of claim 5, wherein the granulovirus isolates ornucleopolyhedrovirus proteins are selected from the group consisting ofenhancins or chitinases.
 9. The synthetic combination of claim 6 inwhich an occlusion body contains virions in which at least the genome ofone virion exhibits the band pattern produced by PstI enzyme.
 10. Abiopesticidal composition comprising at least one synthetic combinationin accordance with claim
 1. 11. The biopesticidal composition of claim10, further comprising excipients, adjuvants, carriers and biological orchemical enhancers of insecticidal activity.
 12. The biopesticidalcomposition of claim 10, further comprising carriers, ultravioletprotectant coadjuvants, diluents, coating polymers, surfactants and/orpH regulators.
 13. The biopesticidal composition of claim 10, in solidform such as powder, a granule, a tablet or a pellet, in liquid formsuch as a suspension, an emulsifiable concentrate or an emulsion, to beapplied to foliage, to soil, by dusting, by irrigation or by spraying,optionally mixed with compost, fertilizers, bio-additives, vegetableextracts or agrochemicals.
 14. The biopesticidal composition of claim10, further comprising: a) a viral suspension with a concentrationbetween 10⁴ and 10¹¹ occlusion bodies/mL comprising at least onesynthetic composition of claim 1; b) clay, iron oxide, coloring,methacrylic acid copolymer, Potassium dihydrogen phosphate and sodiumphosphate dibasic and water.
 15. The biopesticial composition of claim10, further comprising: COMPONENT (% w/w) on a dry basis Viralsuspension with a concentration between 0.50-8.50 10⁴ and 10¹¹ occlusionbodies/mL* Kaolin 70.00-95.00 Red iron oxide  0.10-10.00 Lycopene E160d 0.10-15.00 Methacrylic acid copolymer (Eudragit S100 ®)  1.00-10.00Potassium dihydrogen phosphate 0.01-1.00 Sodium phosphate dibasic0.10-1.00 *a synthetic composition of claim 1


16. The biopesticidal composition of claim 10, further comprising:COMPONENT (% w/w) on a dry basis Viral suspension with a concentrationbetween 1.35 10⁴ and 10¹¹ occlusion bodies/mL* Kaolin 77.95 Red ironoxide 1.36 Lycopene E160d 13.61 Methacrylic acid copolymer (EudragitS100 ®) 5.48 Potassium dihydrogen phosphate 0.04 Sodium phosphatedibasic 0.21 *the synthetic composition of claim
 1.


17. The biopesticidal composition of claim 10, further comprising:COMPONENT (% w/w) on a dry basis Viral suspension with a concentrationbetween 2.5 10⁴ and 10¹¹ occlusion bodies/mL* Kaolin 77.8 Red iron oxide1.36 Lycopene E160d 13.61 Methacrylic acid copolymer (Eudragit S100 ®)4.48 Potassium dihydrogen phosphate 0.04 Sodium phosphate dibasic 0.21*the synthetic composition of claim
 1.


18. The biopesticidal composition of claim 10, further comprising:COMPONENT (% w/w) on a dry basis Viral suspension with a concentration2.5 between 10⁴ and 10¹¹ occlusion bodies/mL* Kaolin 77.8 Red iron oxide2.36 Lycopene E160d 13.61 Methacrylic acid copolymer (Eudragit 3.48S100 ®) Potassium dihydrogen phosphate 0.04 Sodium phosphate dibasic0.21 *the synthetic composition of claim
 1.


19. The biopesticidal composition of claim 10, of the emulsifiableconcentrate type, further comprising: COMPONENT (% w/w) on a dry basisViral suspension with a concentration between 0.66-6.60 10⁴ and 10¹¹occlusion bodies/mL * Methacrylic acid copolymer (Eudragit S100 ®)0.00-5.00 Kaolin  2.0-30.00 Lycopene E160d 0.05-5.00 Boric acid0.05-5.00 Vegetable oil 10.00-70.00 Oleic acid  3.00-10.00 Tween 80 1.00-10.00 Span 60  1.0-10.00


20. The biopesticidal composition of claim 10, of the emulsifiableconcentrate type, further comprising: COMPONENT (% w/w) on a dry basisViral suspension with a concentration between 3.4 10⁸ and 10¹¹ occlusionbodies/mL Methacrylic acid copolymer (Eudragit S100 ®) 0.15 Kaolin 10.6Lycopene E160d 2.84 Boric acid 0.5 Vegetable oil 66.49 Oleic acid 8.01Tween 80 4.24 Span 60 3.77 *the synthetic composition of Claim 1.